{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"MRD status will be reported descriptively. The relationship between MRD status and clinical response to treatment will be examined in children with ALCL.","groups":[{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG000","title":"Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID"},{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG001","title":"Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID"},{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG002","title":"Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID"},{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG003","title":"Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID"},{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG004","title":"Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID"},{"description":"Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.","id":"OG005","title":"Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID"},{"description":"Part B: Patients with ALK+ relapsed/refractory neuroblastoma","id":"OG006","title":"Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID"},{"description":"Part C: Patients with ALK+ relapsed/refractory ALCL","id":"OG007","title":"Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"MRD Patients","reportingStatus":"POSTED","timeFrame":"Up to 8 years","title":"Number of Participants With Minimum Residual Disease (MRD)","type":"SECONDARY","unitOfMeasure":"Participants"}